Skip to Content

Qiagen NV QGEN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Qiagen Delivers Strong Q2 Preliminary Results but Guides to Weak Rest of 2021 on COVID Trends

Julie Utterback, CFA Senior Equity Analyst

Analyst Note

| Julie Utterback, CFA |

No-moat Qiagen turned in preliminary second-quarter results that significantly beat FactSet consensus and management's outlook. However, the shares were down around 7% in the two trading sessions since Qiagen announced a weaker-than-expected 2021 outlook mid-Monday. As we suspected, COVID-19 tailwinds appear to be turning into headwinds for Qiagen, especially in its COVID testing-related franchises. As a result, management reduced its top-line expectations for the year and pushed down its adjusted EPS outlook to the low end of its previously expected range. Our EPS forecast was mildly above that range, but we are maintaining our fair value estimate even after tweaking our expectations for 2021.

Read Full Analysis

Company Profile

Business Description

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates over 85% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (44% of 2020 sales), followed by EMEA (36%) and Asia-Pacific (19%).

Contact
Hulsterweg 82
Venlo, 5912 PL, Netherlands
T +31 773556600
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 5,900

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.